{"slug":"hodgkin","tag":"hodgkin","variants":["hodgkin"],"description":"No description yet","count":4,"kinds":{"person":4},"related":[{"slug":"ghsg","tag":"ghsg","shared":2},{"slug":"adc","tag":"adc","shared":1},{"slug":"canada","tag":"canada","shared":1},{"slug":"cooperative-group","tag":"cooperative-group","shared":1},{"slug":"de-escalation","tag":"de-escalation","shared":1},{"slug":"paediatric","tag":"paediatric","shared":1},{"slug":"trialist","tag":"trialist","shared":1}],"records":[{"id":"joseph-connors","kind":"person","name":"Joseph M. Connors","route":"/people/joseph-connors/","tldr":"Led ECHELON-1, which replaced bleomycin with brentuximab vedotin in first-line advanced Hodgkin lymphoma."},{"id":"peter-borchmann","kind":"person","name":"Peter Borchmann","route":"/people/peter-borchmann/","tldr":"Leads the German Hodgkin Study Group and HD21, which made BrECADD the most effective and least toxic regimen for advanced Hodgkin lymphoma."},{"id":"andreas-engert","kind":"person","name":"Andreas Engert","route":"/people/andreas-engert/","tldr":"Led the GHSG for two decades, running the HD10 to HD18 trials that cure over 90% of Hodgkin lymphoma with less treatment."},{"id":"kara-kelly","kind":"person","name":"Kara M. Kelly","route":"/people/kara-kelly/","tldr":"Leads the COG Hodgkin lymphoma committee and the trials bringing brentuximab and nivolumab to children with the disease."}]}